Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Colorcon
Express Scripts
Julphar
Chubb
Boehringer Ingelheim
UBS
US Army
Covington
McKinsey

Generated: December 11, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,462,626

« Back to Dashboard

Which drugs does patent 7,462,626 protect, and when does it expire?

Patent 7,462,626 protects CONTRAVE and is included in one NDA.

This patent has thirty-four patent family members in twenty-one countries.

Summary for Patent: 7,462,626
Title:Compositions for affecting weight loss
Abstract: Disclosed are compositions for affecting weight loss comprising a first compound and a second compound, where the first compound is an opioid antagonist and the second compound causes increased agonism of a melanocortin 3 receptor (MC3-R) or a melanocortin 4 receptor (MC4-R) compared to normal physiological conditions. Also disclosed are methods of affecting weight loss, increasing energy expenditure, increasing satiety in an individual, or suppressing the appetite of an individual, comprising identifying an individual in need thereof and treating that individual to antagonize opioid receptor activity and to enhance .alpha.-MSH activity.
Inventor(s): Weber; Eckard (San Diego, CA), Cowley; Michael Alexander (Portland, OR)
Assignee: Orexigen Therapeutics, Inc. (San Diego, CA)
Application Number:11/356,839
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,462,626
Patent Claim Types:
see list of patent claims
Use; Formulation; Dosage form;

Drugs Protected by US Patent 7,462,626

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Nalpropion CONTRAVE bupropion hydrochloride; naltrexone hydrochloride TABLET, EXTENDED RELEASE;ORAL 200063-001 Sep 10, 2014 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial FOR CHRONIC WEIGHT MANAGEMENT FOR TREATING OVERWEIGHT OR OBESITY ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

International Family Members for US Patent 7,462,626

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 388698 ➤ Try a Free Trial
Australia 2004233846 ➤ Try a Free Trial
Australia 2010221801 ➤ Try a Free Trial
Canada 2522708 ➤ Try a Free Trial
China 1784221 ➤ Try a Free Trial
Germany 602004012403 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
Daiichi Sankyo
Mallinckrodt
Fish and Richardson
McKinsey
Dow
Colorcon
Teva
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.